Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

• Published in: Journal of diabetes investigation 2019-01, Vol.10 (1), p.108-117
• Main Authors: Sasaki, Takashi, Sugawara, Masahiro, Fukuda, Masahiro
• Format: Article
• Language: English
• Subjects: Asians; Blood Glucose - drug effects; Body composition; Body Composition - drug effects; Body fat; Body weight loss; Bone mineral content; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Dual‐energy X‐ray absorption; Female; Humans; Hypoglycemic Agents - therapeutic use; Intra-Abdominal Fat - metabolism; Japan; Male; Metabolism; Middle Aged; Na+/glucose cotransporter; Original; Patients; Prospective Studies; Sarcopenia; Skeletal muscle; Sodium; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Sorbitol - analogs & derivatives; Sorbitol - therapeutic use; Visceral fat; Weight Loss - drug effects
• ISSN: 2040-1116; 2040-1124
• DOI: 10.1111/jdi.12851

Aims/Introduction It is unclear how changes in body composition induced by sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment correlate with metabolic profile changes. We aimed to clarify how metabolic profile changes correlate with body component changes, and if SGLT2 inhibitor treatment causes sarcopenia and bone mineral content (BMC) loss. Materials and Methods Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes. We analyzed the changes in the individual body components during treatment, and their correlation with other clinical variables. Results The efficacy analysis set comprised 37 of 43 enrolled patients. The total fat mass significantly decreased early in the treatment at and after week 4, with a mean decrease of −1.97 kg (95% confidence interval −2.66 to −1.28) at week 24. The visceral fat area at week 24 showed an average downward trend, although this was not significant. The changes in visceral fat area in individual patients showed a significant negative correlation with the extent of the baseline visceral fat area (r = −0.399, P = 0.023). The skeletal muscle mass index showed a significant but small change at and after week 36. The BMC profile showed a transient significant decrease only at week 12. No significant change in BMC was noted at other time‐points. Conclusions Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction. Luseogliflozin treatment was found to be capable of controlling T2D with favorable changes in the body composition and metabolism accompanied by minimal muscle and BMC reduction, even in moderately obese patients. The changes in the visceral fat area at Week 24 in individual patients showed a significant negative correlation with the respective visceral fat area levels at the baseline (r = −0.457, P = 0.0085).